Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?
Open Access
- 14 May 2015
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 21 (10) , 2244-2255
Abstract
Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy with a unique natural history characterized by a short doubling time, high growth fraction, and early development of widespread metastases. Although a chemotherapy- and radiation-sensitive disease, SCLC typically recurs rapidly after primary treatment, with only 6% of patients surviving 5 years from diagnosis. This disease has been notable for the absence of major improvements in its treatment: Nearly four decades after the introduction of a platinum–etoposide doublet, therapeutic options have remained virtually unchanged, with correspondingly little improvement in survival rates. Here, we summarize specific barriers and challenges inherent to SCLC research and care that have limited progress in novel therapeutic development to date. We discuss recent progress in basic and translational research, especially in the development of mouse models, which will provide insights into the patterns of metastasis and resistance in SCLC. Opportunities in clinical research aimed at exploiting SCLC biology are reviewed, with an emphasis on ongoing trials. SCLC has been described as a recalcitrant cancer, for which there is an urgent need for accelerated progress. The NCI convened a panel of laboratory and clinical investigators interested in SCLC with a goal of defining consensus recommendations to accelerate progress in the treatment of SCLC, which we summarize here. Clin Cancer Res; 21(10); 2244–55. ©2015 AACR. See all articles in this CCR Focus section, “Progress in Lung Cancer.”Keywords
This publication has 137 references indexed in Scilit:
- Functional characterization of pulmonary neuroendocrine cells in lung development, injury, and tumorigenesisProceedings of the National Academy of Sciences, 2012
- A framework for identification of actionable cancer genome dependencies in small cell lung cancerProceedings of the National Academy of Sciences, 2012
- Comprehensive genomic characterization of squamous cell lung cancersNature, 2012
- Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancerNature Genetics, 2012
- A crucial requirement for Hedgehog signaling in small cell lung cancerNature Medicine, 2011
- Targeting MYC dependence in cancer by inhibiting BET bromodomainsProceedings of the National Academy of Sciences, 2011
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic ScreeningNew England Journal of Medicine, 2011
- A small-cell lung cancer genome with complex signatures of tobacco exposureNature, 2009
- Aurora A Is Essential for Early Embryonic Development and Tumor SuppressionJournal of Biological Chemistry, 2008
- The Epigenomics of CancerCell, 2007